Arthramid 2.5% PAAG Hydrogel


PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues. These characteristics determine the safety and effectiveness of each hydrogel.

Arthramid Vet 2.5% PAAG

Arthramid Vet (AV) is a unique and patented hydrogel produced by IL-X cross-linking technology and consisting of 2.5% polyacrylamide. This combination results in a gel similar to hyaluronic acid in structure and tissue compatibility, but with a superior and longer lasting effect, as it integrates into the joint itself and is non-degradable.

 Arthramid Vet is supplied in a sterile pre-filled 1ml syringe sealed with a Luer lock fitting.

Once injected into the joint the 2.5% PAAG acts as a tissue scaffold enabling integration into the sub-intima by a combination of cell migration and vessel ingrowth, forming a thick cushion-like membrane (see figures opposite). 

The treated synovium also develops a new and hypercellular synovial cell layer. 

AV is used to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA). OA can be caused by traumatic injury or usual wear and tear which causes the joint to become inflamed. As the cartilage or cushion between the joints breaks down, pain, stiffness, and swelling develop, causing lameness. 

Lameness remains the most common cause of reduced performance in the equine industry. In addition to pain reduction, treatment should also serve to arrest or slow down the progression of lesions allowing for disease modification. It is now well recognised that the OA disease process can start with the disease in the synovial membrane and that inflamed synovium is an essential component in the pathogenesis, with it almost always being present in cases of OA.

As part of the OA complex, the elastic and viscous nature of the synovial fluid is abnormally low. Furthermore, the synovial membrane becomes a source of inflammatory products which contribute to the progressive degradation of the joint over time. 

Studies have shown disease-modifying effects as Arthramid Vet integrates into the synovial membrane, stabilising the joint capsule, and increasing elasticity, which, in turn, reduces the onset of synovitis and its harmful effects. The formation of rejuvenated synovium improves the nature of the synovial fluid within the joint itself. 

Additionally, Arthramid Vet essentially causes a ‘cushion-like’ effect in the joint which allows for the preservation and/ or regeneration of the joint cartilage contributing to reducing the pain of synovitis and OA, and ultimately restoring the joint function.


Testimonials From Clinical Practice

“Arthramid Vet enables me to effectively manage problem joints” (read full)
“I have been using Arthramid Vet for many years now treating TB’s,SB’s and equestrian horses. It’s simply the best treatment we have for OA” (read full)

“I was one of the first vets to use Arthramid worldwide and the results are quite astonishing” (read full)

  • Addresses Equine Welfare Concerns
  • Long-lasting Clinical Effects of Treatment
  • 82.5% Successful Resolution of Joint Lameness

Get In Touch

Contact Us

First Name:
Last Name:
Your Email:
Business Name:

Phone +64 (09) 8013 253

Arthramid Vet Australia

Registered in Australia to: IMS Vet Pty Limited, 1953 Grampian's Road, Fyans Creek, Victoria 3381. Registered pursuant to the APVMA Number 86728/0320. See for registration conditions.

Address for Service:
IMSVet, PO Box 1083, Cambridge 3450, New Zealand
Phone +61 (0408) 899 940